Evidence map›Paper›PMID 36080318›Full record

ArticleMolecules (Basel, Switzerland)2022

Dual Inhibition of HIV-1 and Cathepsin L Proteases by

Bowen Pan, Sumei Li, Junwei Xiao, Xin Yang, Shouxia Xie, Ying Zhou, Jian Yang, Ying Wei

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Identification of Flavonoids fromMolecules (Basel, Switzerland) · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bowen PanCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Sumei LiDepartment of Pharmacology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.ORCID 0000-0003-3997-9087
Junwei XiaoCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Xin YangCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Shouxia XieDepartment of Pharmacology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, China.
Ying ZhouCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
Jian YangCollege of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.
Ying WeiCollege of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.

Funding

Guizhou Provincial Science and Technology Projects Qian Ke He Zi Cheng (2020)4Y213Guizhou Provincial Science and Technology Projects ZK [2022] general 480Innovation Group Project of Guizhou Province Qian Jiao He KY (2021)018Research Center of Molecular Bioactivity from Traditional Chinese Medicine and Ethnomedicine 3411-4110000520364Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties SZXK059the projects of Guizhou province gzwkj2022-232the projects of Guizhou province gzwkj2022-467the projects of Guizhou province Qian Jiao He KY Zi [2022]253the projects of Guizhou University of Traditional Chinese Medicine 2018YFC170810108the projects of Guizhou University of Traditional Chinese Medicine 2018YFC170810204
6 · The paper itself

Abstract

The COVID-19 pandemic continues to impose a huge threat on human health due to rapid viral mutations. Thus, it is imperative to develop more potent antivirals with both prophylactic and treatment functions. In this study, we screened for potential antiviral compounds from

Indexed as

COVID-19HIV-1Antiviral AgentsCathepsin LHumansMolecular Docking SimulationPandemicsPeptide HydrolasesSARS-CoV-2Antiviral AgentsCathepsin LPeptide HydrolasesCathepsin L proteaseHIV-1 proteaseinhibitionmolecular dockingSarcandra glabraUPLC-HRMS

Identifiers

PMID36080318
PMCPMC9457736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.